ICUI ICU MEDICAL INC/DE
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 883984 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-5.9%
TTM net income YoY919.5%
TTM EPS YoY846.9%
Revenue 3-yr CAGR-1.0%
Net income 3-yr CAGR—
Margins
Gross margin40.3%
Operating margin5.1%
Net margin2.8%
FCF margin9.6%
EBITDA margin11.2%
Returns
ROE2.8%
ROA1.5%
ROIC (approx.)3.6%
Asset turnover0.54x
Leverage & solvency
Liabilities / assets44.4%
Debt / equity0.53x
Current ratio2.37x
Interest coverage1.41x
Cash quality & payout
Operating cash flow / net income4.63x
Accruals ratio-5.4%
Payout ratio—
Capex / revenue3.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.23B | $2.38B | $2.26B | $2.28B | $1.32B |
| Cost of revenue | $1.41B | $1.56B | $1.52B | $1.58B | $824.82M |
| Gross profit | $822.04M | $824.78M | $739.87M | $697.76M | $491.49M |
| R&D expense | $87.50M | $88.61M | $85.34M | $92.98M | $47.50M |
| SG&A expense | $625.21M | $638.76M | $606.69M | $608.35M | $302.58M |
| Operating income | $42.83M | $42.96M | $22.82M | -$42.90M | $123.25M |
| Interest expense | $93.34M | $106.54M | $102.73M | $70.81M | $858,000 |
| Pretax income | $4.36M | -$66.01M | -$78.30M | -$135.65M | $81.48M |
| Income tax | $2.44M | $51.68M | -$48.64M | -$40.12M | $20.05M |
| Net income | $732,000 | -$117.69M | -$29.66M | -$74.29M | $103.14M |
| EBITDA | $243.57M | $262.48M | $251.60M | $192.25M | $212.94M |
| EPS (basic) | 0.03 | -4.83 | -1.23 | -3.11 | 4.86 |
| EPS (diluted) | 0.03 | -4.83 | -1.23 | -3.11 | 4.74 |
| Weighted avg. shares (diluted) | 24.90M | 24.39M | 24.09M | 23.87M | 21.78M |
| Banking | |||||
| Net interest income | -$83.03M | -$95.75M | -$95.22M | -$66.38M | $1.98M |
| Balance sheet | |||||
| Cash & equivalents | $307.96M | $308.57M | $254.22M | $208.78M | $552.83M |
| Short-term investments | — | $0 | $501,000 | $4.22M | $14.42M |
| Receivables | $180.51M | $182.83M | $161.57M | $221.72M | $105.89M |
| Inventory | $615.86M | $584.68M | $709.36M | $696.01M | $290.24M |
| Current assets | $1.19B | $1.44B | $1.22B | $1.24B | $1.03B |
| PP&E, net | $451.82M | $442.75M | $612.91M | $636.11M | $468.37M |
| Goodwill | $1.50B | $1.43B | $1.47B | $1.45B | $43.44M |
| Intangibles | $633.56M | $740.79M | $870.59M | $982.77M | $188.31M |
| Total assets | $4.05B | $4.20B | $4.38B | $4.52B | $1.88B |
| Current liabilities | $498.86M | $556.18M | $481.84M | $494.56M | $200.78M |
| Short-term debt | $18.75M | $51.00M | $51.00M | $29.69M | $0 |
| Long-term debt | $1.27B | $1.53B | $1.58B | $1.62B | $0 |
| Total debt | $1.28B | $1.58B | $1.63B | $1.65B | $0 |
| Total liabilities | $1.93B | $2.24B | $2.26B | $2.43B | $264.71M |
| Shareholders' equity | $2.12B | $1.97B | $2.12B | $2.09B | $1.62B |
| Net debt | $976.70M | $1.27B | $1.37B | $1.44B | -$552.83M |
| Shares outstanding | 24.69M | 24.52M | 24.14M | 23.99M | 21.28M |
| Cash flow statement | |||||
| Operating cash flow | $179.85M | $204.03M | $166.20M | -$62.13M | $267.54M |
| Capital expenditure | $88.04M | $79.37M | $83.89M | $90.31M | $68.54M |
| Free cash flow | $91.80M | $124.66M | $82.31M | -$152.44M | $199.00M |
| Investing cash flow | $122.23M | -$88.96M | -$87.95M | -$1.91B | -$90.69M |
| Financing cash flow | -$311.52M | -$55.80M | -$35.98M | $1.64B | -$16.87M |
| Depreciation & amortization | $200.74M | $219.51M | $228.77M | $235.15M | $89.70M |
| Stock-based compensation | $55.76M | $46.88M | $40.56M | $36.02M | $27.34M |
| Share buybacks | $8.77M | $11.99M | $9.35M | $10.88M | $8.34M |
Free plan shows the latest 5 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.